Skip to main content

Table 3 Associations of KRAS mutation status with clinicopathological and molecular characteristics in 153 patients

From: Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer

n (%) KRAS wild type KRAS mutated P-value
  136(89%) 17(11%)  
Age    
Mean 63.38 60.71 0.293
Median 62.00 62.00  
Range 47-83 49-69  
Histological subtype    
Mucinous 5(3.7) 7(41.2) <0.001
Serous 87(64.0) 3(17.6)  
Endometroid 30(22.1) 5(29.4)  
Other 14(10.3) 2(11.8)  
Differentiation grade    
Well-moderate 36(26.5%) 11(64.7) 0.001
Poor 100(73.5) 6(35.3)  
Clinical Stage    
I 20(16.0) 6(40.0) 0.088
II 16(12.8) 2(13.3)  
III 70(56.0) 4(26.7)  
IV 19(15.2) 3(20.0)  
Missing 11 15  
ER    
≤10% 56/43.1) 11(64.7) 0.092
>10% 74(56.9) 6(35.3)  
Missing 6 0  
PR    
≤10% 111(84.1) 10(62.5) 0.035
>10% 21(15.9) 6(37.5)  
Missing 4 1  
AR    
≤10% 112(82.4) 13(76.5) 0.554
>10% 24(17.6) 4(23.5)  
Missing 0 0  
Chek1    
Low 36(28.8) 8(53.3) 0.053
High 89(71.2) 7(46.7)  
Missing 11 2  
Chek2    
Low 43(33.6) 9(56.2) 0.075
High 85(66.4) 7(43.8)  
Missing 8 1